Author:
AR Rozaliyani1,2*, FS Setianingrum1,2, AA Abdullah1,2, SA Azahra1,3, AEF Fatril1, HR Rosianawati4, EB Burhan2,4, DH Handayani2,4, MT Tugiran1,2, RA Adawiyah1,2, RS Syam1,2, RW Wahyuningsih1,2,5, HW Wibowo1,2, CK Kosmidis6,7, DW Denning6,7
Author address:
1Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
2Indonesia Pulmonary Mycoses Centre, Jakarta, Indonesia
3Magister Program of Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
4Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
5Department of Parasitology, Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia
6Manchester Academic Health Science Centre, Division of Infection, Immunity, University of Manchester, Manchester, United Kingdom
7Manchester Fungal Infection Group, University of Manchester, Manchester, United Kingdom
Full conference title:
10th Advances Against Aspergillosis and Mucormycosis
Date: 2 February 2022
Abstract:
Purpose:
Aspergillus andTalaromycesare two closely related genera with diverse important species potentially causing disease in human. Aspergillus fumigatus is the most common species known as the etiological cause of chronic pulmonary aspergillosis. Indonesia is included as the endemic area of Talaromycesmarneffei. However, studies on the clinical spectrum and molecular profiles of cryptic species of Aspergillus and T. marneffei are limited. This study’s aim was to describe the clinical and radiological features, and molecular profiles of fungi isolated from severe chronic pulmonary aspergillosis (CPA) patients.
Methods:
We reviewed the culture collection of CPA patients with positive T. marneffei cultures from Parasitology Department, Universitas Indonesia from 2018-2020. Demographic, clinical features and radiological data were assessed from medical records. The species identity of isolates was determined by combined analysis of morphology of the colonies (T. marneffei), and the sequencing of ITS and beta-tubulin genes (Aspergillus spp). The Aspergillus IgG were measured using point-of-care test (immunochromatography, LDBio, France).
Results:
In total, four cases of T.marneffei were identified, three of them mixed with cryptic Aspergillus species. Patient’s age ranged from 42 to 75 years; all males were included. All patients were admitted to hospital with severe symptoms. Three patients had acute or massive haemoptysis and one patient had dyspnea with oxygen desaturation. History of previous tuberculosis was present in all patients. One patient with history of multi drug resistant TB was admitted to the emergency room with severe anemia (Hb: 5g/dL). This patient showed positive culture from sputum (Aspergillus fumigatus, A. tubingensis, and T. marneffei). Another patient had an aspergilloma proven by chest CT and presented with acute haemoptysis and positive fungal culture (A. aculeatus and T. marneffei). Radiological deterioration was observed in this patient with massive pleural effusion. The morphology identification had previously identified the cryptic species as A. niger. The Aspergillus IgG antibody was positive in three patients (75%) including one patient with only T. marneffei detected in the culture. Other chronic diseases in the patients were uncontrolled diabetes, chronic obstructive pulmonary disease, and hypertension.
Conclusion:
This study demonstrates the clinical importance of cryptic and endemic fungi in CPA cases. Molecular identification offers precise identification of fungi to species level. Further study is required to assess the susceptibility profile of cryptic Aspergillus and the significance of T. marneffei towards better diagnosis and management of lung mycoses cases in Indonesia.
Abstract Number: 12
Conference Year: 2022
Link to conference website: https://aaam2022.org/
Link Conference abstract:
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
C Gutierrez Perez1*, S Dhingra1,2, SM Kwansy3, TJ Opperman3, RA Cramer1
2022
93
-
v
PC Chatterjee1*, WC Chiu1, EBB Burgener2, PLB Bollyky3, JH Hsu1
2022
92
-
v
AS Serris1*, FU Uhel2, GMB Martin-Blondel3, OL Lambotte4, MEB Bougnoux5, EL Litvinova6, AO Ouedrani7, CR Rouzaud1, VB Bedarida8, JHR Raphalen9, FL Lanternier1,10
2022
91
-
v
ZA Lewis1, RB Meagher2*, S Ambati2, X Lin1
2022
90
-
v
QJ Choudhury1*, S Ambati2, X Lin1, ZA Lewis1, RB Meagher2
2022
-
v
M James1*, KW Liu1, E Vesley1, T Hohl2, RA Cramer1
2022
88
-
v
D Luptakova1, RH Patil1,2, V Havlicek1,2*
2022
87
-
v
EI Matthaiou1*, W Chiu1, C Conrad2, J Hsu1
2022
86
-
v
H Kamboj*, M Vijay, L Gupta, P Vijayaraghavan
2022
85
-
v
S Hartung1,2*, TNM Hoang1,2*, Z Cseresnyes3*, N Schuck1, K Rennert4,5, F Klos6, AS Mosig5,7, MT Figge3,8, M von Lilienfeld-Toal1,2
* Authors 1, 2 and 3 contributed equally
2022
84
